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Acute intra-renal infusion of bradykinin increases diuresis and natriuresis via inhibition
of vasopressin activity. However, the consequences of chronically increased bradykinin
in the kidneys have not yet been studied. A new transgenic animal model producing
an excess of bradykinin by proximal tubular cells (KapBK rats) was generated and
submitted to different salt containing diets to analyze changes in blood pressure and
other cardiovascular parameters, urine excretion, and composition, as well as levels
and expression of renin-angiotensin system components. Despite that KapBK rats
excrete more urine and sodium, they have similar blood pressure as controls with the
exception of a small increase in systolic blood pressure (SBP). However, they present
decreased renal artery blood flow, increased intrarenal expression of angiotensinogen,
and decreased mRNA expression of vasopressin V1A receptor (AVPR1A), suggesting
a mechanism for the previously described reduction of renal vasopressin sensitivity by
bradykinin. Additionally, reduced heart rate variability (HRV), increased cardiac output
and frequency, and the development of cardiac hypertrophy are the main chronic effects
observed in the cardiovascular system. In conclusion: (1) the transgenic KapBK rat is
a useful model for studying chronic effects of bradykinin in kidney; (2) increased renal
bradykinin causes changes in renin angiotensin system regulation; (3) decreased renal
vasopressin sensitivity in KapBK rats is related to decreased V1A receptor expression; (4)
although increased renal levels of bradykinin causes no changes in mean arterial pressure
(MAP), it causes reduction in HRV, augmentation in cardiac frequency and output and
consequently cardiac hypertrophy in rats after 6 months of age.
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INTRODUCTION
The kallikrein-kinin system (KKS) is present throughout the
body. Bradykinin (BK) is its main effective peptide and has
two sources: it is released from circulating high molecular
weight kininogen by the action of plasma kallikrein; or
from low molecular weight kininogen by the action of tissue
kallikrein (1). BK is an agonist of the kinin B2 receptor (B2R),
and its metabolite Des-Arg9-BK has affinity to the kinin B1
receptor (B1R). First related to vasodilation, inflammation,
pain, and edema, the KKS has also been shown to participate
in several cellular and physiological events, such as glucose
homeostasis (2–4), leptin sensitivity (5), and organ and tissue
protection or injury (6). The effects of BK on renal physiology
and blood pressure (BP) control are still not completely
unraveled.
A number of experiments were carried out to understand the
role of BK in kidney and in particular how it is involved in
the control of renal homeostasis and BP, as previously reviewed
(1, 7). Usual approaches to test intrarenal effects of BK are the
renal artery infusion of BK or antagonists of its receptors (8–10),
intrarenal tissue BK infusion (11), the use of knockout animals
(12, 13), or in vitro studies (14, 15). However, all approaches
have limitations, mainly due to the complex morphology of the
kidney, where the proximal and distal parts of the nephrons are
anatomically mixed, and the local circulation has very specific
characteristics and morphology. More recent studies have shown
that infusion of BK into the kidneys causes increased urinary
volume and increased sodium secretion, with no change in BP
(16). Studies in dogs showed that infusion of BK in the kidneys
increases urinary volume (UV) and sodium excretion (UNaV),
without changing glomerular filtration rate (GFR) and these
effects are blocked by pretreatment with the B2R antagonist
HOE-140 (17). The increase in UV is associated with vasopressin
inhibition in the kidney. Schuster et al. has shown that lysyl-
BK inhibits the effect of vasopressin with respect to hydraulic
conductivity (Lp) in the rabbit cortical collecting tubule perfused
in vitro (18). The inhibition of vasopressin activity by BK
infusion was also confirmed in an in vivo study (17). Hebert
et al. concluded that this effect is transmitted via B2R and
is independent of calcium signaling in the cortical collecting
ducts.
Both previous in vivo and in vitro experiments revealed
several acute effects of BK in kidneys, but the models used are
not predicting chronic effects of excess BK in this organ. This
knowledge is important to evaluate the possibility of using B2R
agonists for renal diseases.
Therefore, we generated a transgenic rat overexpressing
BK in the proximal convoluted tubules, in order to test
the hypothesis that chronic excess of bradykinin may cause
changes in BP and physiology of the cardiovascular system.
These animals were submitted to diets with different sodium
contents. Changes in BP, heart rate variability (HRV), genetic
expression of selected components of the renin-angiotensin,
vasopressin, and KKSs, as well as cardiac morphology, and
physiology of the cardiovascular and urinary systems were
evaluated.
METHODS
Animals
All studies were performed in accordance with the guidelines
for the humane use of laboratory animals by the Max Delbrück
Center for Molecular Medicine (Berlin, Germany) and with EU
Directive 2010/63/EU for animal experiments. The animals were
maintained under standardized conditions with an artificial 12-
h dark-light cycle with free access to standard chow (0.25%
sodium, SSNIFF Spezialitäten GmbH, Soest, Germany) and water
ad libitum, except during the experimental diet period when
they received special sodium containing diets. Two different diets
were fed, low salt diet and high salt diet (E15430-24 sodium
deficient; E15431-34, 4% salt, SSNIFF Spezialdiäten GmbH,
Germany). If not stated different, male rats at the age of 4 months
were used for experiments. All procedures with the animals were
analyzed and approved by the Ethical Committee Landesamt für
Gesundheit und Soziales (LaGeSo), Berlin, Germany.
Generation of Transgenic Rats
The basic DNA construct for the generation of transgenic rats
codes for an engineered fusion protein consisting of the signal
peptide of human renin, the Fc portion of the mouse IgG, a
prosegment of the human prorenin, a furin cleavage site followed
by the sequence of Tyr0-BK, as previously described (19). The
promoter of kidney androgen regulated protein (Kap) was used
to direct the expression of this construct specifically in the
proximal tubules (20). This peptide delivery system has already
been successfully used in several transgenic animal models (21–
23). Tyr0-BK, rather than BK itself, had to be selected, since furin
would only very inefficiently cut N-terminal to the natural start
of the BK peptide, arginine, but will cut in front of tyrosine
(19). Tyr0-BK is known to be a full agonist on BK receptors
(24). The Kap promoter sequence was cloned into the same
vector and the resulting construct (Figure 1A) was linearized
and microinjected into male pronuclei of Sprague-Dawley rat
zygotes as previously described (25). Genomic integration of the
transgene DNA construct was determined by PCR analysis using
DNA obtained from offspring tail biopsies.
Assessment of Basic Renal Function
To collect urine, rats were kept in metabolic cages with
1 day of adaptation before collecting samples for analysis.
Overnight collected urine samples were centrifuged (4,000 g), the
supernatant collected in fresh tubes and stored frozen at −20◦C.
For measurement of urine concentrations of ions and creatinine,
samples were sent and processed by Labor28 (Berlin, Germany).
Immunohistochemistry
For histochemical analysis, rats were anesthetized with Nembutal
(100 mg/Kg body weight), the abdominal cavity opened
and kidneys were fixed by retrograde perfusion through
the abdominal aorta using 3% paraformaldehyde in PBS as
previously described (26). Kidneys were then processed for
cryostat sectioning. Cryosections were incubated with primary
anti-mouse IgG2b and secondary anti-rabbit Cy2-fluorescence-
coupled antibodies and examined in a Leica fluorescence
microscope.
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FIGURE 1 | Targeted overexpression of BK in proximal convoluted tubules. (A) Construct for BK secretion in proximal tubule. The Kap promoter and an intron from
β-globin was used to target renal proximal tubule expression of a recombinant protein containing: a signal peptide from human renin gene (hR) to allow the
recombinant protein to be secreted; part of mouse IgG2b to provide mass; a human prorenin-derived spacer (Pro) to allow furin activity; a furin cleavage site, the
sequence of the Tyr0-BK peptide (BK) followed by a stop codon and a polyadenylation site (polyA). (B) RT-PCR analysis of selected tissues of KapBK rats. Image of
agarose gels showing the PCR products of β-actin (right) and mouse IgG2b (left) after reverse transcriptase reaction (RT+) of total RNA extract from KapBK rat
tissues. As control for DNA contamination the same procedure was done with samples submitted to the same protocol without addition of reverse transcriptase (RT-,
bottom of the gels). A, Adrenal gland; H, Heart; Li, Liver; Lu, Lung; S, Spleen; T, Thymus; M, Muscle; K, Kidney; +, positive control; – = H2O.
(C) Immunohistochemistry using anti-mouse IgG2b antibodies to show the specific expression of the recombinant protein in kidney proximal tubules. Upper panels
show overview of the cortex with immunoreactive signal over proximal tubules exclusively in the KapBK tissue. Lower panels show higher magnification with
immunoreactive proximal segments grouped around a single glomerulus; magnification x 150 (top), x 800 (bottom).
High Frequency Ultrasound Analysis
Animals were anesthetized by inhaling a 2.5% isoflurane
oxygen mixture in a heat-controlled chamber to keep the body
temperature stable. After reaching full anesthesia, rats were fixed
on a heated plate with electrodes on their paws to control heart
and respiratory rate, as well as to record the electrocardiogram.
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Body temperature wasmonitored by a rectal sensor and corrected
by a heating lamp if necessary. With the ultrasonic detector MS-
250 collected data were visualized and analyzed via the VEVO
2,100 high-resolution imaging system (Visualsonics Fujifilm,
VisualSonics, Toronto, Ca). Stroke volume and cardiac output
was measured by tracing the endocardium in systole and diastole
of a parasternal long axis view of the left ventricle.
Telemetry
The telemetry system for BP and heart rate measurement
(Dataquest ART 4.0TM, Data Sciences Inc., St. Paul, MN, USA)
and the implantation procedure are described in detail by Plehm
et al. (27). Briefly, the radiotelemetric pressure transducers
(TA11PA-C40) were implanted in the abdominal cavity of the
rats, with the pressure-sensing capillary anchored in the lumen
of the abdominal aorta. Before the implantation the zero offset
was measured and the unit was soaked in 0.9% NaCl solution.
Rats were anesthetized with isoflurane. Animals recovered for
10 days before baseline values were recorded. By this time the
rats had regained their circadian BP and heart rate rhythm
while surgery and anesthesia-induced changes in systolic blood
pressure (SBP), diastolic blood pressure (DBP), mean arterial
pressure (MAP), and heart rate (HR) had abated. The data from
the implanted transducer were transmitted via radiofrequency
signals to a receiver below the home cage and sampled every
5min (sampling rate 500Hz).
Spectral Analysis
Continous telemetric recordings of the BP waveform were stored
during resting and activity periods for 1 h. These waveform
recordings were used for computing the HRV and the spectral
analysis of the HR to analyze the autonomic regulation. For
analysis of the HRV and the frequency domain results we used
the Kubios HRV analysis software (Kubios, Kuopio, Finland).
TheHRV spectrumwas calculated from artifact-corrected 30min
recordings using Fast Fourier Transformation. The frequency
bands were very low frequency (VLF, 0,015–0,250Hz), low
frequency (LF, 0,250–1,000Hz), and high frequency (HF, 1,000–
6,000Hz).
Measurement for Renin-Angiotensin
System (RAS) Components
The renin activity of plasma samples was calculated from the
generation rate of AngI in the samples, for renin concentration a
defined amount of angiotensinogen was added before incubation.
Plasma angiotensinogen was measured by adding rat kidney
extract to the samples and measuring AngI generation. The
concentration of AngI was measured by radioimmunoassay.
These methods were performed as described before (28, 29).
Gene Expression Analyses
For quantitative real-time PCR (qPCR) tissues were snap-frozen
in liquid nitrogen. Samples were homogenized and total RNAwas
isolated using a NucleoSpin RNA II purification kit (Macherey-
Nagel, Düren-Germany) and then stored at−80◦C until use. The
RNA integrity was assessed by electrophoresis on an agarose gel.
cDNA was synthesized from 1 µg of total RNA with Moloney
murine leukemia virus reverse transcriptase (Promega, Madison,
USA) using random hexamer nucleotides. Standard curves were
made to determine the amplification efficiencies for each primer
pair. Quantitative PCR was performed on an ABI Prism 7900
sequence detection system with 100 nM primers, 5 ng of cDNA,
and 10 µL SYBRGreen mastermix (Thermo Fisher Scientific,
Waltham, USA) in a 20 µL reaction. mRNA expression was
normalized to beta-actin mRNA and expressed as a relative value
to the control group.
Statistics
Normality of data was determined using the Shapiro–Wilk test
and equality of variance verified using Brown-Forsythe test,
and all data presented normal distribution. Statistical analyzes
were performed using GraphPad Prism R© software (GraphPad
Software Inc, La Jolla, USA). Results were considered significant
when p < 0.05 and data are shown as means ± standard error of
the mean (SEM). Differences between two groups were evaluated
by using unpaired Student’s test, and differences between more
than two groups were evaluated by using ANOVA.
RESULTS
Basic Characterization of KapBK Rats
The DNA construct coding for an engineered fusion protein
controlled by the kidney androgen-regulated protein (Kap)
promoter was inserted into the genome of Sprague-Dawley
rats (overview see in Figure 1A) to elicit BK overproduction
specifically in the proximal convoluted tubule. This promoter
is androgen dependent and was shown to be specific for
proximal convoluted tubules (20). Adult male rats expressed
the recombinant protein in the kidney (Figure 1B). Transgenic
female rats cannot activate the Kap promoter and can be used as
control. Low expression in the lung was also detected. Since BK
in lung is very quickly inactivated as described before (30), the
effect in lung is probably minimal. Figure 1C presents an image
of the immunohistochemical detection of the fusion protein
in kidney sections using an antibody directed against mouse
immunoglobulin G2b, which is part of the engineered protein
(Figure 1A), confirming its specific expression in proximal
tubules of KapBK rats.
KapBK Rats Exhibit Polyuria, Diluted Urine,
and Excrete More Na+, but Are Able to
Control Urine Volume Under Water
Deprivation
The overexpression of BK in renal proximal tubules causes
polyuria which is compatible with other experiments infusing
BK in anesthetized animals (17). The increase in urine excretion
was present when rats were feeding a standard chow as well as
with diets containing low and high amounts of salt (Figure 2A).
The increased diuresis is compensated by reflex polydipsia
(Figure 2A). In the case of high salt diet, KapBK rats need a
smaller adaptive increase in urinary volume in order to excrete
the excess of ingested salt. Furthermore, the urine of KapBK rats
is diluted with regards to several other components like protein
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FIGURE 2 | Urine and blood parameters. The animals were submitted to diets containing different concentrations of sodium. After 10 days with each diet urine was
collected in metabolic cages. KapBK rats secrete more urine and drink more water (A) and the urine has lower concentrations of total proteins, urea, potassium and
sodium concentrations. (B) Total sodium and sodium/potassium ratios are increased. (C) Plasma concentrations of total proteins, creatinine, sodium, and potassium
were unchanged in rats fed with standard diet. (D) Data presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT, n = 6.
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content, sodium, potassium, and urea suggesting reduction of
water reabsorption (Figure 2B). Analyzing daily sodium and
potassium excretion, we noted an increased sodium excretion
and an increased Na+/K+ excretion ratio (Figure 2C) in
agreement with previous studies (7, 15, 31, 32). No changes were
observed regarding plasma levels of proteins, creatinine, sodium
or potassium (Figure 2D), and blood cell count (Table S1) and
only body composition analysis (Figure S1) showed a trend to
increased water content.
Under 20-h water deprivation, KapBK rats present diuresis
only in the first 4 h of the experiment. Then they start to
produce the same amount of urine as the controls, showing that
these rats are able to adapt to water deprivation avoiding severe
dehydration (Figure 3). These results demonstrate that KapBK
rats are a useful model for analyses of the chronic effect of
increased renal BK on water/electrolyte homeostasis.
KapBK Rats Present a Small Increase in
Systolic Blood Pressure, Increased Heart
Rate, and Decreased Heart Rate Variability
Chronically increased BK in renal proximal tubules of rats
did not change MAP but increased SBP (Figure 4A) as
detected by telemetric measurement (Figure S2). However,
the cardiovascular system underwent several alterations
in the adaptive response to the polyuria. Increased heart
rate (Figure 4B) was observed, accompanied by decreased
HRV (Figure 4C) and a decreased low-frequency oscillatory
component (that can be a signal of changes in RAS) (Figure 4D).
The LF/HF ratio (Figure 4E) was decreased in KapBK rats
indicating decreased sympathovagal balance on the heart
FIGURE 3 | Urine excretion under water deprivation. Under normal diet, the
animals were submitted to water deprivation and showed adaptation in urine
volume production over time. Data presented as mean ± SEM. *p < 0.05,
***p < 0.001 vs. WT, n = 6.
contrasting the increased heart rate. The relative and absolute
masses of the adrenal glands were reduced in KapBK rats
suggesting reduction of adrenergic activation (Figure 4F).
Chronic BK Excess in Kidney Causes
Cardiac Hypertrophy and Increased
Cardiac Output, Contrasting With Smaller
Renal Artery Blood Flow, and Normal
Glomerular Filtration Rate
Probably as a consequence of the increased heart rate, cardiac
hypertrophy develops in older KapBK rats (6 months old) as
evidenced by increased left ventricular fractional shortening, left
ventricular mass, and cardiac output (Figures 5A–C). Despite
the increased cardiac output, KapBK rats have reduced renal
artery blood flow (Figure 5D) suggesting high pressure in
the glomerular capillary system. The activity of the systemic
RAS is changed (Figures 5F–H) with decreased plasma renin
activity and concentration (2-fold) and increased concentration
of plasma angiotensinogen (3-fold). Connecting the low blood
flow in the renal artery with the polyuria, we found normal GFR
as estimated by creatinine clearance (Figure 5E).
Chronic Overexpression of BK in Kidney
Increases Local Angiotensinogen and
Decreased Epithelial Sodium Channel
(SCNN1, Alpha, and Gamma Subunits) and
AVPR1A mRNA Expression
We analyzed the mRNA expression of selected genes by qPCR
in the following regions of the kidney: Fragments of outer
cortex (OC), inner cortex (IC), and medulla (M) (Figure 6).
Increased angiotensinogen expression was observed in all parts
of kidney (Figure 6A), showing that the local RAS is activated
in KapBK rats. We also found increased expression of B2R in
OC (Figure 6B), probably due to the increased BK levels that
were shown to stimulate the expression of B2R by Ricciardolo
et al. in other tissues (33). The reduced expression of vasopressin
V1A receptor (AVPR1A, Figure 6C) can explain the diluted urine
although vasopressin V2 receptor (AVPR2) expression remained
unchanged (Figure 6D). Increased sodium excretion can be
related to reduced expression of alpha and gamma subunits of
the epithelial sodium channel (ENaC, SCNN1, Figures 6E–G).
The increased aquaporin 2 (AQP2) expression in medulla after
water deprivation is part of the mechanism involved in the
adaptation against severe dehydration (Figure 6H). No changes
were observed in renal mRNA expression of renin (Figure 6I).
DISCUSSION
Acute infusion of bradykinin in the kidneys causes polyuria
inhibiting vasopressin activity in collecting tubules (17, 18, 34)
and increasing sodium excretion (1, 7, 9, 10, 15, 32, 35).
However, the consequences of chronic BK excess in the kidneys
are still incompletely studied (36, 37). In the present study a
new animal model producing an excess of BK in the proximal
tubules was generated. The overproduction of BK in these rats
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FIGURE 4 | Cardiovascular and autonomic system. The blood pressure parameters were measured by telemetry after 10 days of normal (B), low salt (L), or high salt
(H) containing diet. (A) Mean arterial pressure (MAP), systolic blood pressure (systole) and diastolic blood pressure (diastole). (B) Heart rate under normal diet (basal,
B) and low (L) and high (H) salt diets. (C) Heart rate variability (HRV; STD HR = standard deviation of Heart Rate). (D) Power (%) of oscillatory components (VLF, very
low frequency; LF, low frequency and HF, high frequency). (E) Ratios of oscillatory components. (F) Adrenal gland mass normalized to body weight. Data presented as
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT, n = 6.
starts from puberty and is maintained during the remainder of
life, allowing studies about long-term effects of BK in kidney.
For better understanding of these chronic effects, the animals
were submitted to three diets with different salt concentrations.
Changes in renal and cardiovascular functions as well as in
the renin-angiotensin and KKSs were assessed. Additionally,
the expression of several genes was evaluated in different parts
of the kidney. The main results showed that the chronic BK
excess in the kidneys causes cardiac hypertrophy, changes in the
regulation of the local, and systemic renin angiotensin systems,
increased heart rate and cardiac output, decreased heart rate
variability, maintenance of GFR despite of reduced blood flow
in the renal artery, and changes in gene expression in kidney,
mainly increasing angiotensinogen and decreasing vasopressin
V1A receptor mRNA levels. Moreover, there was no change in
MAP, in agreement with the described acute models of BK excess
in the kidney (17, 36).
The results confirmed that the overexpression of BK in the
kidney of the animals was successfully achieved. Although we
could notmeasure BK levels directly, this conclusion is supported
by genotyping, RT-PCR, immunohistochemistry and also by the
concordance of physiological changes observed in the present
study with previous literature, mainly polyuria, increased sodium
excretion and the diluted urine of the transgenic animals. These
effects were observed after acute BK treatment in kidney (17) but
also in studies searching for chronic effects (36). Furthermore,
the DNA construct was designed to be expressed in proximal
tubules and to secrete BK into the extracellular space, based
on the signal peptide present in the expressed protein and the
ubiquitous expression of furin, and it is well-established that
intraluminally generated kinins in kidney exert autocrine and
paracrine actions on distal tubular cells, favoring natriuresis
and diuresis (32) as observed in the present study. In addition,
interstitially released BK contributes to the regulation of cortical
and medullary blood flow (38), as was also observed in KapBK
rats and will be discussed below. These results confirm that the
novel rat model is appropriate to study chronic excess of BK in
kidney.
Although BK is known to dilate vessels and promote sodium
excretion and polyuria, very few experiments show a sustained
alteration in MAP by BK. Different methods were used to test
the potential hypotensive effect by infusing BK in kidney, but BP
normally returned to normal values after an acute decline (37,
39, 40). Moreover, it was also observed that knockout mice for
either kinin receptor, B1 and B2, as well as double knockout mice
are normotensive (41–45), although they can react differently
than controls in relation to BP control when submitted to
challenges such as high-salt diet. Only general overexpression of
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FIGURE 5 | Cardiac and renal function, renin-angiotensin system. (A) left ventricular fractional shortening; (B) left ventricular mass; (C) normalized cardiac output;
(D) renal artery flow; (E) glomerular filtration rate (GFR) as estimated by creatinine clearance (F) plasma renin concentration; (G) plasma renin activity; (H) plasma
angiotensinogen concentration. Data presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT, n = 6.
tissue-kallikrein in transgenic rats leads to a small but significant
reduction in MAP probably by the permanent rise of BK in
several tissues (42). Although KapBK rats presented similar MAP
as the controls, we observed several changes in the cardiovascular
system concerning BP regulation. The local renal RAS seems
to be activated with increased expression of angiotensinogen.
This increased intrarenal RAS activity is also evidenced by the
diminished renal artery blood flow since AngII is known to
cause vasoconstriction of both afferent and efferent glomerular
arterioles increasing intraglomerular pressure (46). On the other
hand, the observed reduction of plasma renin concentration and
activity suggests a reduction in systemic RAS activity. Despite
the severe reduction in renal artery blood flow in KapBK rats,
GFR does not change. The reduction in glomerular blood flow
seems to be a mechanism to maintain normal GFR which is also
observed in AVPR1A knockout mice (47).
It is well established that BK inhibits vasopressin-induced
water flow in the collecting duct in vitro (18, 34) and in vivo
via B2R (17). The present study shows that after several months
of chronic overexpression of BK in kidney the rats still present
polyuria. The dilution of all urinary components indicates
increased water content suggesting decreased water reabsorption.
This is compatible with the inhibition of vasopressin activity
as previously described both in vitro and in vivo in acute
models of BK infusion in the kidney (17, 18, 34). However,
the present study shows a marked decrease in the expression
of vasopressin V1A receptors in the parts of the kidney that
are rich in distal nephron structures, but no change in V2
receptor expression, showing that vasopressin resistance can
be regulated directly via gene expression of V1A receptors.
Previous studies showed that the effect of BK on inhibition of
vasopressin activity is dependent on prostaglandin formation
(and can be blocked with indomethacin) and independent
of increased calcium concentration (17). This suggests that
the increase in endogenous prostaglandin synthesis by B2R
activation antagonizes vasopressin-stimulated cAMP generation
and reduces vasopressin-induced water flow in the collecting
duct (18, 34). The new observation that decreased expression
of vasopressin V1A receptors is related to these effects opens
new doors to understand the underlying mechanisms. Further
gene expression studies are warranted using acute models of
excessive BK supply to elucidate whether the changed AVPR1A
expression found here is indeed a chronic effect, or is also
part of acute BK effects on vasopressin-induced water flow in
the kidney. Favoring that vasopressin receptors mediate the
effects of chronic BK excess, AVPR1A knockout mice exhibited
a similar phenotype as KapBK rats concerning urine volume and
composition (48). Accordingly, polyuria in KapBK rats seems to
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FIGURE 6 | Renal gene expression: Total RNA was extracted from outer (OC) and inner (IC) cortex, and medulla (M) of kidney. (A) AGT, angiotensinogen;
(B) BDKB2R, bradykinin B2 receptor; (C) AVPR1A, vasopressin V1A receptor; (D) AVPR2, vasopressin V2 receptor; (E–G) SCNN1-A, B, and G, subunits alpha, beta,
and gamma of the Epithelial Sodium Channel (ENaC); (H) AQP2, aquaporin 2; (I) renin. All data were normalized for WT OC group and are shown as relative fold
change. Data presented as mean ± SEM. *p < 0.05, **p < 0.01 vs. WT, n = 5.
be an effect caused in the distal nephron by reduction of AVPR1A
receptors as evidenced in the mRNA expression analysis. Aoyagi
et al. showed that polyuria observed in AVPR1A knockout mice
was associated with decreased water reabsorption and not with
increased GFR, as observed in KapBK rats. They also described a
lower renin concentration in plasma of AVPR1A knockout mice
again agreeing with KapBK rats (14). Furthermore, Yasuoka et al.
noted that in water restriction conditions AVPR1A knockout
mice also increase renal AQP2 expression as observed in KapBK
rats (47). All these similarities suggest that the consequences
of increased BK in kidney are due to the altered regulation of
AVPR1A expression in KapBK rats.
To localize gene expression to certain structures of the kidney,
we used RNA originating from three different regions of the
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kidney, called here: the “outer cortex,” the more external part
of the kidney cortex containing mainly the proximal structures
of the nephrons; the “inner cortex,” containing all parts of the
nephrons including small fractions of the distal nephrons; and
the “medulla,” containing mainly collecting ducts and loops of
Henle. Onemain result of this expression study was the reduction
of alpha and gamma subunits expression of ENaC mainly in
parts of the kidneys containing distal nephron structures. Again,
these new data suggest that the inhibition of ENaC activity by
BK infusion can be induced by gene expression regulation. It
is well-established that the increase in UNaV by BK is due to
the inhibition of ENaC (7, 15, 32). Other authors have shown
inhibition of sodium reabsorption by BK (7, 31, 49). Zaika
et al. presented a related effect on SCNN1 in an experiment
in vitro (15), showing that BK decreases the probability of SCNN1
channel opening. In the present study, the ENaC activity was
not measured since it was well-demonstrated previously (7, 17).
However, the measurements of Na+, Cl−, and K+ in urine
indicated that only Na+ showed increased excretion in KapBK
rats, suggesting that the inhibition of Na+ reabsorption is not
due to cotransporters such as Na/K-ATPase, thiazide-sensitive
sodium chloride co-transporter (NCCT) or sodium-potassium-
chloride co-transporter (NKCC2), all of them important sodium
transporters in the apical membrane of different regions of the
nephrons (50). Together with previous studies demonstrating
that BK inhibits only ENaC (7, 15, 17, 32), the here presented
reduction of the gene expression of ENaC subunits, and the
urine concentration of the excreted ions together indicate that
the observed natriuresis in KapBK rats is caused by reduction of
ENaC, at least partially on the level of gene expression.
Although vasopressin sensitivity is reduced in KapBK rats
by decreased AVPR1A expression, expression of AVPR2 is
similar to that of control animals. Accordingly, AQP2 mRNA
expression is increased in renal medulla of KapBK rats after water
deprivation. AVPR2 is the main regulator of AQP2 translocation
to the apical membrane providing a strong mechanism of water
reabsorption in the presence of increased vasopressin levels.
Both, the induction of AQP2 expression and normal expression
of AVPR2 explain why KapBK rats can concentrate urine
under water deprivation, and fit with observations in AVPR1A
knockout mice, which also can concentrate urine under this
condition (14). Therefore, we speculate that KapBK rats are
equipped with a reduced sensitivity to basal vasopressin levels,
due to low AVPR1A expression, but they respond adequately to
increased level of vasopressin, since there is a normal AVPR2
expression and an inducible AQP2 expression in kidney.
The increased renal BK expression affects the heart as
evidenced by increased heart rate and contractility in KapBK
rats, leading to an augmented cardiac output and even cardiac
hypertrophy when KapBK rats get older. These are typical
phenomena of cardiac sympathetic stimulation, but we found
decreased LF/HF ratio and a smaller mass of the adrenal gland
suggesting a reduction in the sympathovagal balance. This
discrepancy may at least partially be related to the differential
regulation of the sympathetic innervation of different organs.
Taken together, our results show that chronic intrarenal
overexpression of BK exerts similar alterations in renal
physiology as known from acute models of intrarenal BK
infusion. However, also unexpected effects appeared in the
chronic model showing that the new transgenic KapBK rats
are suitable for studying chronic actions of BK in the kidney.
These new effects of intrarenal BK include changes in RAS
regulation, decreased renal vasopressin sensitivity based on
decreased V1A receptor expression and reductions in cardiac
rhythm variability, augmentation in heart rate and cardiac
output and consequently cardiac hypertrophy without changes
in MAP. These data have implications for the concept that B2
receptor agonists may have a beneficial effect in controlling
hypertension. It is already well-established that ACE inhibitors
exert their main effects by reducing angiotensin II, but in
addition, much of the protective effects on the kidneys are
associated with the increase of the BK concentrations in this
organ (51–54). In the present study, the chronic increase of
renal BK happened in the presence of an active RAS, since
there is no ACE inhibition. The present data suggest even an
increased local RAS activity, based on increased angiotensinogen
expression and decreased renal artery blood flow. The systemic
RAS activity, on the other hand, seems to be decreased based
on decreased plasma renin concentration and activity. Under
these conditions, novel adaptations and physiological effects
of BK have been reported here, which should be followed
up in the case of administration of B2 receptor agonists
as experimental treatment in patients without ACE inhibitor
treatment.
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